Revista Farmespaña Industrial Julio-Agosto 2023

LB BOHLE tendencias en la producción farmacéutica, la fabricación en continuo se hace realidad “No hay nada más constante que el cambio“, ya lo dijo Charles darwin. Pocas veces los tiempos en la industria farmacéutica han sido tan turbulentos como en la actualidad. La OMS declara el fin del COVID-19 como una emergencia sanitaria mundial y tres tendencias clave están configurando el futuro de la industria. MANUEL MORALES Y LORENA DÍAZ LB BOHLE % "#,0)1$0#-/B'08#'-#1$"2%#-'%#{B0'"($%# 4'01'*;/&)*'%{#,02(/*)0J"#1$"2%#-2> &$%#B0'"($%#($#*21,0)1)(2%#2#{?$%&> $--$0%}#$"#$-# 4/&/02<#!"#%/# -/B'08#'/1$"&'0J# -'# ($1'"('# ($# *21,0)1)(2%# )"()9)(/'-)A'> (2%<#!-#E"%&)&/&2#ErgEK#,0$()*$#./$8#,'0'#565_8# 1J%#($-#h6|#($-#B'%&2#$"#$-#-'"A'1)$"&2#($# "/$92%#1$()*'1$"&2%#%$#($%&)"'0J#'-#B0/,2# ($# -2%# {1$()*'1$"&2%# $%,$*)'-)A'(2%{<# ^$# &0'&'# ,0)"*),'-1$"&$# ($# &$0',;/&)*'%# 2"*2> -+B)*'%#2#1$()*'1$"&2%#,'0'#$"4$01$('($%# 0'0'%#2#,'0'# -'#&$0',)'#($#$"4$01$('($%#'/> &2)"1/"$%<#!"# -'#,02(/**)+"8#,20# &'"&28#C'> ?0J#1$"2%#($1'"('#($#)"%&'-'*)2"$%#'#B0'"# $%*'-'#2#12"2>,02(/*&2<#jJ%#?)$"8#-2#./$#%$# "$*$%)&'"#%2"#,-'"&'%#1J%#,$./$D'%#@#*21> ,-$H'%#./$#,02(/A*'"#*2"#-'#1'@20#*$-$0)('(# @#%$B/0)('(#,2%)?-$8#@#,/$('"#0$'-)A'0#,02*$> %2%#($#-)1,)$A'#'/&21'&)A'(2%< !"# %$B/"(2# -/B'08# %)B/$# '/1$"&'"(2# -'# ($1'"('# ($# $./),2%# *','*$%# ($# ,02*$%'0# ,0)"*),)2%# '*&)92%# 2# 1/@# ,2&$"&$%<# jJ%# ($-# h6|# ($# -2%# ,02(/*&2%# 4'01'*;/&)*2%# %$# 4'> ?0)*'"# $"# 4201'# ($# *21,0)1)(2%8# *J,%/-'%8# *21,0)1)(2%# 0$*/?)$0&2%# 2# %)1)-'0$%<# !%,$> *)'-1$"&$# $"# $-# *'%2# ($# -2%# ,02(/*&2%#1J%# "/$92%8#-2%#,0)"*),)2%#'*&)92%#4'01'*;/&)*2%# cKMEd#%2"#*'('#9$A#1J%#($*)%)92%#$"#&;01)"2%# ($#$4$*&2<#!"#'-B/"2%#1$0*'(2%8#$-#%$B1$"> &2# ($# -2%# ,0)"*),)2%# '*&)92%# 4'01'*;/&)*2%# ($# '-&'# ,2&$"*)'# ciMKMEd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cSjd<#U$%,/;%#./$# (/0'"&$# 1/*C2# &)$1,2# %+-2# %$# C'?-'0'# ($# $--'#*212#$%&0'&$B)'#($# 4/&/028# -2%#,02*$%2%# *2"&)"/2%#%$#/&)-)A'"#*'('#9$A#1J%#$"#-'#,02> (/**)+"#($#%+-)(2%#4'01'*;/&)*2%<#I<O<#O2C-$# $%#,)2"$0'#$"# -'# 4'?0)*'*)+"#*2"&)"/'#($%($# C'*$#1J%# ($# ()$A# 'D2%<# !"# -2%# =-&)12%# %$)%# 'D2%8# -'# $1,0$%'# C'# )"&$"%)4)*'(2# '="#1J%# %/%#'*&)9)('($%#$"#$%&$#*'1,2#)"9)0&)$"(2#($# /"'# 4201'# *2"%)($0'?-$# $"# $-# ($%'002--2# ($# ,02(/*&2%8#,$0%2"'-#$#)"40'$%&0/*&/0'< N2#1$"2%# )1,20&'"&$8#($?)(2#'# -'%#20)$"> &'*)2"$%# ($# -'# 3UK# %2?0$# &$*"2-2B:'%# '"'-:> &)*'%#($#,02*$%2%#cMKRd#@#'#-'%#()0$*&0)*$%#($# -'#ESi#c-'#=-&)1'#ESi#rZ7#{U)0$*&0)*$%#,'0'#-'# 4'?0)*'*)+"# *2"&)"/'d# %2?0$# ($%'002--2# 4'0> 1'*;/&)*28# ?'%'('# $"# -'# *'-)('(# ($# B$%&)+"# ($# 0)$%B2%# @# %)%&$1'%# ($# *'-)('(8# -'# )($'# ($# -'# Sj# ($#1$()*'1$"&2%# C'# $G,$0)1$"&'(2# /"# B0'"# )1,/-%2<# I'# )"(/%&0)'# 4'01'*;/&)*'# $%,$0'#2?&$"$0#1/*C2%#?$"$4)*)2%#($#-'#)1> ,-'"&'*)+"#($#,02*$%2%#($#Sj<#I'#*','*)('(# ($#12")&20)A'0#1J%#($#*$0*'#/"#,02*$%2#($# ,02(/**)+"#1$()'"&$# MKR# @8# ($# $%&$#12(28# 4'?0)*'0#%)%&$1J&)*'1$"&$#,02(/*&2%#($#'-&'# *'-)('(# $%# $-# ,/"&2# *$"&0'-# ($# $%&'%# )($'%# $# )1,-)*'# 1/*C2%# 2&02%# ?$"$4)*)2%8# ,20# 1$"*)2"'0# '-B/"2%8# *212# /"'# 1'@20# %$> B/0)('(# ($-# ,'*)$"&$8# 1$"20$%# *2%&$%# @# /"# 1$H20# $"&$"()1)$"&2# ($-#*2"&02-#@#,02*$%2 8NTOURNRUVW+R]WbUWLN+ QW+SN+UWPL[bOUN+ \NO^NRmLb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jM#1J%#0$(/*)('%#*2"#1$> "2%#*2%&$%#($#&0'"%,20&$#@#'-1'*$"'1)$"&28# ,'%'"(2# ,20# /"'# 1'@20# 4-$G)?)-)('(# ($# -'# ,02(/**)+"#$"#$-#*)*-2#($#9)('#($-#,02(/*&2< K-# )B/'-# ./$# -2%# ()%&)"&2%# ,02*$%2%# '# ")9$-# 1/"()'-8# ($# 4'?0)*'*)+"# ?'%'(2# $"# -2&$%8# -'# 4'?0)*'*)+"# *2"&)"/'# ($# 4201'%# ($# (2%)4)*'> *)+"# %+-)('%# &'1?);"# 240$*$# ()%&)"&2%#1;&2> (2%#($#4'?0)*'*)+"<#I2%#1J%#($%&'*'(2%#%2"# -'# ,02(/**)+"# ($# *21,0)1)(2%# c0$*/?)$0&2%# *2"#,$-:*/-'d#?'%'('#$"#B0'"/-'*)+"#9:'#%$*'# *2"&)"/'8#B0'"/-'*)+"#@# %$*'(2#9:'#C=1$('# *2"&)"/'#@#*21,0$%)+"#()0$*&'#*2"&)"/'< S2"# -'# &$*"2-2B:'# r?S2"8# I<O<# O2C-$# c!"> ")B$0-2C8#K-$1'")'d#240$*$# -'#,2%)?)-)('(#($# ,02(/*)0#($%($#-'#1'&$0)'#,0)1'#?J%)*'8#,2-> la idea de la CM de medicamentos ha experimentado un gran impulso. La industria farmacéutica espera obtener muchos beneficios de la implantación de procesos de CM caso Práctico 134 FARMESPAÑA INDUSTRIAL · JUL/AGO 23